INVIVYD

[anonymous]

0.58

 

[anonymous]

FOCUS - FOCUS - FOCUS

Classic Schacher!!!!!

 

[anonymous]

.50 FOCUS - FOCUS - FOCUS

 

[anonymous]

.50 FOCUS - FOCUS - FOCUS

.45 FOCUS - FOCUS - FOCUS

 

[anonymous]

On December 12, McGuire sold 125,000 shares at an average price of approximately $0.583 per share. Following this transaction, McGuire retained ownership of 4,077,679 shares indirectly. A subsequent sale on December 16 involved 65,359 shares at an average price of $0.4668 per share, leaving McGuire with 4,012,320 shares in indirect ownership. InvestingPro data reveals the company is quickly burning through cash, which could be influencing insider decisions.

 

[anonymous]

On December 12, McGuire sold 125,000 shares at an average price of approximately $0.583 per share. Following this transaction, McGuire retained ownership of 4,077,679 shares indirectly. A subsequent sale on December 16 involved 65,359 shares at an average price of $0.4668 per share, leaving McGuire with 4,012,320 shares in indirect ownership. InvestingPro data reveals the company is quickly burning through cash, which could be influencing insider decisions.

.40 wrf

 

[anonymous]

Charles Schwab Investment Management Inc. decreased its holdings in shares of Invivyd, Inc. by 57.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 210,749 shares of the company’s stock after selling 289,312 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.18% of Invivyd worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

 

[anonymous]

FOCUS - FOCUS - FOCUS

Classic Schacher!!!!!

Dan, you meds were sent to Boston and u moved to Chicago. R u gonna be ok?

 

[anonymous]

Dan, you meds were sent to Boston and u moved to Chicago. R u gonna be ok?

Agnes, just bring them when u cum to Chicago for Christmas.

 

[anonymous]

The FDA revoked the authorization for Lilly's bebtelovimab, AstraZeneca's Evusheld, GSK's sotrovimab and Regeneron's REGEN-COV. The companies also do not intend to offer the products in the U.S. anymore, according to the FDA.

Is Pemgarda next?

 

[anonymous]

The FDA revoked the authorization for Lilly's bebtelovimab, AstraZeneca's Evusheld, GSK's sotrovimab and Regeneron's REGEN-COV. The companies also do not intend to offer the products in the U.S. anymore, according to the FDA.

Is Pemgarda next?

Yes. Ibuzatrelvir.
FOCUS - FOCUS - FOCUS

 

[anonymous]

Agnes, just bring them when u cum to Chicago for Christmas.

Dan, thanks for demonstrating the Schacher shuffle that u do in the clinic!

 

[anonymous]

Dan, you meds were sent to Boston and u moved to Chicago. R u gonna be ok?

Glenview

 

[anonymous]

Dan, thanks for demonstrating the Schacher shuffle that u do in the clinic!

He’s a bullieee

 

[anonymous]

He’s a bullieee

What's the tea?

 

[anonymous]

What's the tea?

FOCUS - FOCUS - FOCUS tea please

 

[anonymous]

Commercial folks loved to talk during the performance review overview meeting today.

 

[anonymous]

Commercial folks loved to talk during the performance review overview meeting today.

Did u have tea?

 

[anonymous]

Did u have tea?

HR still mum about reorg that happened last month. Check out the latest org chart in Lattice so you're aware of what the major changes are.

 

[anonymous]

He’s a bullieee

Garold, man up!